NCT04139902: An ongoing trial by Diwakar Davar
This trial is ongoing. It must report results 5 months, 4 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04139902 |
|---|---|
| Title | PHASE II NEOADJUVANT STUDY OF PD-1 INHIBITOR DOSTARLIMAB (TSR-042) VS. COMBINATION OF TIM-3 INHIBITOR COBOLIMAB (TSR-022) AND PD-1 INHIBITOR DOSTARLIMAB (TSR-042) IN RESECTABLE STAGE III OR OLIGOMETASTATIC STAGE IV MELANOMA (NEO-MEL-T) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 12, 2020 |
| Completion date | Sept. 29, 2025 |
| Required reporting date | Sept. 29, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |